New Stock News | Fukang Pharmaceutical's Hong Kong Stock IPO Prospectus Invalid

Fukang Biotechnology (Shanghai) Co., Ltd. (referred to as Fukang Pharmaceuticals) submitted its Hong Kong IPO prospectus on August 31, 2025, which has expired recently after 6 months. Agricultural Bank International, CMBC CAPITAL, and FOSUN INTL Capital were its joint sponsors. The prospectus shows that Fukang Pharmaceuticals was founded in November 2015, and it is a commercial-stage biopharmaceutical company with a vision of developing breakthrough therapies and driven by high-efficiency innovation. The company focuses on the development of breakthrough therapies for cancer-related diseases, as well as the development and commercialization of innovative drugs for viral and aging diseases. The company adopts a dual-track strategy of commercialization and clinical development, rather than solely focusing on research and development. The core products of the company include: (i) CVL009, classified as a Class 2.4 improved new drug. The company is currently conducting Phase II clinical trials on CVL009 for non-small cell lung cancer patients with rare HER1 mutations, HER2 positive gastric cancer brain metastases patients, and in combination therapy with capecitabine; and (ii) CVL218, a novel second-generation highly selective PARP inhibitor for treating advanced solid tumors.